Trial Profile
A Single Arm, Phase II Clinical Study of Tremelimumab Combined With the Anti-PD-L1 MEDI4736 Monoclonal Antibody in Unresectable Malignant Mesothelioma Subjects: The NIBIT-MESO-1
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Malignant-mesothelioma; Mesothelioma
- Focus Therapeutic Use
- Acronyms NIBIT-MESO-1
- 10 Sep 2019 Results presented at the 20th World Conference on Lung Cancer.
- 07 Mar 2018 The recruitment status of this study is unknown because trial information has not been verified since 27 Oct 2015.
- 18 Oct 2017 Results of the final analysis, presented at the 18th World Conference on Lung Cancer